Premium
Monoclonal antibody therapy of inflammatory bowel disease.
Author(s) -
van Deventer SJ,
Camoglio L
Publication year - 1996
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1996.22164027.x
Subject(s) - monoclonal antibody , medicine , inflammatory bowel disease , immunology , crohn's disease , monoclonal antibody therapy , immune system , monoclonal , antibody , epitope , disease , tumor necrosis factor alpha , ulcerative colitis , inflammation
Several anti‐inflammatory drugs have therapeutic efficacy in inflammatory bowel disease, but their targets remain incompletely characterized. The development of monoclonal antibodies that either recognize epitopes on immune‐competent cells, or neutralize pro‐ inflammatory cytokines, has helped to define the importance of inflammatory mediators and their cellular sources in experimental inflammatory bowel disease. Moreover, two monoclonal antibodies, directed against CD4 and tumour necrosis factor, have been used to treat patients with steroid‐refractory Crohn's disease. Preliminary data suggest that immune‐modulatory monoclonal antibodies may have beneficial effects in selected patients with severe Crohn's disease.